Market Cap 1.43B
Revenue (ttm) 614.38M
Net Income (ttm) -18.52M
EPS (ttm) N/A
PE Ratio 14.63
Forward PE 12.88
Profit Margin -3.01%
Debt to Equity Ratio 0.71
Volume 219,500
Avg Vol 371,054
Day's Range N/A - N/A
Shares Out 21.66M
Stochastic %K 93%
Beta 0.55
Analysts Strong Sell
Price Target $82.62

Company Profile

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chain...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 218 634 3500
Fax: 218 634 3540
Address:
210 Main Street West, Baudette, United States
Dy2ski
Dy2ski Jun. 20 at 11:15 PM
$ANIP Solid day and week for the stock. Good to see, especially when overall market is seemingly taking a breather and profits.
0 · Reply
Dy2ski
Dy2ski Jun. 3 at 12:00 AM
$ANIP Finally, a decent show of strength with this stock today...now let's see if CEO Lalwani and CFO Carey can make a mark (news?) and work the rooms at this week's conferences!
0 · Reply
RunnerSignals
RunnerSignals May. 27 at 8:33 PM
Technical Analysis Wrap-Up $ANIP holding steady but still oversold $UNH deep dive keeps caution high $AMD $NVDA are flexing their breakout muscles with strong momentum! stocksrunner.com/news/2025-05-27-tuesday-technical-analysis-wrap-up
0 · Reply
DonCorleone77
DonCorleone77 May. 22 at 11:02 AM
$ANIP ANI Pharmaceuticals initiates Phase 4 trial of Purified Cortrophin Gel ANI Pharmaceuticals announced the initiation of a Phase 4 clinical trial at Massachusetts General Hospital to compare the safety and efficacy of two dose levels (40 USP units and 80 USP units) of Purified Cortrophin Gel for the treatment of acute gout flares. Cortrophin Gel is indicated for short-term administration as an adjunctive therapy during an acute episode or exacerbation in acute gouty arthritis. Cortrophin Gel is contraindicated for intravenous administration.
0 · Reply
WestEgg
WestEgg May. 20 at 1:31 PM
$ANIP can we confirm who the accounting firm is for ani?
1 · Reply
Victor224
Victor224 May. 20 at 10:25 AM
$ANIP ANIP may be on verge of announcing a larger pharma partner for LIBIGEL. On May 15, 2025, ANIP submitted a trademark application for Libigel (female testosterone). The trademark was cancelled in 2016. It could be related to the Certification request to delay submitting results from the LIBIGEL trials in October 2021 and a New Drug Application submitted to the FDA in Q3 2023 by ANIP. According to SEC flings, it appears a third part paid the application fee (estimated at $3.2 million) for an undisclosed drug. It would also explain why ANIP's Linkedin page and their FAQ page no longer show their Containment (hormone) Facility in Baudette, MN.
2 · Reply
Victor224
Victor224 May. 20 at 10:11 AM
$ANIP ANIP is now selling INZIRQO (hydrochlorothiazide) for Oral Suspension and TEZRULY (terazosin) Oral Solution, but have yet to announce their launch. Both have no competition and are patent protected until 2041 or later. They both address unmet needs for patients who have trouble swallowing pill and capsule versions formulations of theses drugs (e.g. hospital, assisted living) INZIRQO is indicated for Hypertension and Edema. In 2022, over 38 million prescriptions hydrochlorothiazide were filled in the US. If INZIRQO captures 3 % of the market it could generate approximately $475 million. TEZRULY is an alpha-1 blocker indicated for Benign Prostatic Hyperplasia and Hypertension. In 2022, over 28 million prescriptions for the top alpha-1 blockers were filled in the US. IF TEZRULY capture 3% of this market it could add another $400 million in revenue. Non of these drugs appear factored into current PPS.
0 · Reply
SalmanAziz
SalmanAziz May. 13 at 1:40 PM
$ANIP lets go red to green mate!
0 · Reply
SalmanAziz
SalmanAziz May. 13 at 11:22 AM
$ANIP looking for a 60 dollar entry
0 · Reply
Tlinz50
Tlinz50 May. 12 at 7:36 PM
$ANIP Hard to believe this SP action down close to $10.00 on a beat and raise ER. Ripely wouldn’t believe it. Btw they really sandbagged their guidance for the year,IMO. Plus the two other drugs that they have approval for, but have not announced.
1 · Reply
Latest News on ANIP
ANI Pharmaceuticals: A Short-Term Buying Opportunity

May 6, 2025, 5:43 AM EDT - 7 weeks ago

ANI Pharmaceuticals: A Short-Term Buying Opportunity


ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets

Mar 19, 2025, 6:50 AM EDT - 3 months ago

ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets


ANI Pharmaceuticals: More Than Just A Generics Company

Feb 11, 2025, 9:08 AM EST - 4 months ago

ANI Pharmaceuticals: More Than Just A Generics Company


Alcami Announces CEO Transition

Jan 13, 2025, 11:12 AM EST - 5 months ago

Alcami Announces CEO Transition


ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market

Oct 11, 2024, 4:01 AM EDT - 9 months ago

ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market


ANI Pharmaceuticals, Inc. (ANIP) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 12:40 PM EDT - 11 months ago

ANI Pharmaceuticals, Inc. (ANIP) Q2 2024 Earnings Call Transcript


Dy2ski
Dy2ski Jun. 20 at 11:15 PM
$ANIP Solid day and week for the stock. Good to see, especially when overall market is seemingly taking a breather and profits.
0 · Reply
Dy2ski
Dy2ski Jun. 3 at 12:00 AM
$ANIP Finally, a decent show of strength with this stock today...now let's see if CEO Lalwani and CFO Carey can make a mark (news?) and work the rooms at this week's conferences!
0 · Reply
RunnerSignals
RunnerSignals May. 27 at 8:33 PM
Technical Analysis Wrap-Up $ANIP holding steady but still oversold $UNH deep dive keeps caution high $AMD $NVDA are flexing their breakout muscles with strong momentum! stocksrunner.com/news/2025-05-27-tuesday-technical-analysis-wrap-up
0 · Reply
DonCorleone77
DonCorleone77 May. 22 at 11:02 AM
$ANIP ANI Pharmaceuticals initiates Phase 4 trial of Purified Cortrophin Gel ANI Pharmaceuticals announced the initiation of a Phase 4 clinical trial at Massachusetts General Hospital to compare the safety and efficacy of two dose levels (40 USP units and 80 USP units) of Purified Cortrophin Gel for the treatment of acute gout flares. Cortrophin Gel is indicated for short-term administration as an adjunctive therapy during an acute episode or exacerbation in acute gouty arthritis. Cortrophin Gel is contraindicated for intravenous administration.
0 · Reply
WestEgg
WestEgg May. 20 at 1:31 PM
$ANIP can we confirm who the accounting firm is for ani?
1 · Reply
Victor224
Victor224 May. 20 at 10:25 AM
$ANIP ANIP may be on verge of announcing a larger pharma partner for LIBIGEL. On May 15, 2025, ANIP submitted a trademark application for Libigel (female testosterone). The trademark was cancelled in 2016. It could be related to the Certification request to delay submitting results from the LIBIGEL trials in October 2021 and a New Drug Application submitted to the FDA in Q3 2023 by ANIP. According to SEC flings, it appears a third part paid the application fee (estimated at $3.2 million) for an undisclosed drug. It would also explain why ANIP's Linkedin page and their FAQ page no longer show their Containment (hormone) Facility in Baudette, MN.
2 · Reply
Victor224
Victor224 May. 20 at 10:11 AM
$ANIP ANIP is now selling INZIRQO (hydrochlorothiazide) for Oral Suspension and TEZRULY (terazosin) Oral Solution, but have yet to announce their launch. Both have no competition and are patent protected until 2041 or later. They both address unmet needs for patients who have trouble swallowing pill and capsule versions formulations of theses drugs (e.g. hospital, assisted living) INZIRQO is indicated for Hypertension and Edema. In 2022, over 38 million prescriptions hydrochlorothiazide were filled in the US. If INZIRQO captures 3 % of the market it could generate approximately $475 million. TEZRULY is an alpha-1 blocker indicated for Benign Prostatic Hyperplasia and Hypertension. In 2022, over 28 million prescriptions for the top alpha-1 blockers were filled in the US. IF TEZRULY capture 3% of this market it could add another $400 million in revenue. Non of these drugs appear factored into current PPS.
0 · Reply
SalmanAziz
SalmanAziz May. 13 at 1:40 PM
$ANIP lets go red to green mate!
0 · Reply
SalmanAziz
SalmanAziz May. 13 at 11:22 AM
$ANIP looking for a 60 dollar entry
0 · Reply
Tlinz50
Tlinz50 May. 12 at 7:36 PM
$ANIP Hard to believe this SP action down close to $10.00 on a beat and raise ER. Ripely wouldn’t believe it. Btw they really sandbagged their guidance for the year,IMO. Plus the two other drugs that they have approval for, but have not announced.
1 · Reply
JarvisFlow
JarvisFlow May. 12 at 2:29 PM
Guggenheim has adjusted their stance on ANI Pharmaceuticals ( $ANIP ), setting the rating to Buy with a target price of 86.
0 · Reply
Tarde75
Tarde75 May. 9 at 6:06 PM
0 · Reply
Doozio
Doozio May. 9 at 4:14 PM
$ANIP unmm. Not a very 🧠 FRYday here.
0 · Reply
Dy2ski
Dy2ski May. 9 at 3:08 PM
$ANIP Great quarter and Conference Call. Hard to complain, really. The Medicare Part B issue is what it is. Every aspect of this Sector (and the overall market for that matter) is getting pummeled with uncertainly and confusing economic surprises. Management deserves to have time to get their new combined Sales Team and combined Rx for the Ophlamolgy Treatments and Cortrophin and so on. Good to hear CFO Carey aknowledge the patent litigation and trial that now begins in July. Have to imagine a settlement between the two but $ANIP is in a can't lose position regardless (beyond legal fees). Well done.
0 · Reply
CunningStunt69
CunningStunt69 May. 9 at 2:13 PM
$ANIP beats, raises guidance, is already at a cheap multiple, and has earnings growth. Falls. Need to double check the CC but might be add time.
0 · Reply
CunningStunt69
CunningStunt69 May. 9 at 1:04 PM
$ANIP very noice
0 · Reply
Hurtadogoalkeeper
Hurtadogoalkeeper May. 9 at 1:02 PM
MY BULLISH DAY TRADING LIST: $ANIP https://www.globenewswire.com/news-release/2025/05/09/3078088/0/en/ANI-Pharmaceuticals-Reports-Record-First-Quarter-2025-Financial-Results-and-Raises-2025-Guidance.html $TTD https://finance.yahoo.com/news/trade-desk-nasdaq-ttd-reports-200643632.html $CRVS https://www.tipranks.com/news/company-announcements/corvus-pharmaceuticals-reports-promising-q1-2025-results https://www.tipranks.com/news/company-announcements/corvus-pharmaceuticals-reports-positive-phase-1-trial-results
0 · Reply
Doozio
Doozio May. 9 at 12:42 PM
$IBEX eps gap n go TTWO $ANIP them bum 🐑 who are $TOST INTA 🐒🍌🧠⏰♾️
0 · Reply
OpenOutcrier
OpenOutcrier May. 9 at 12:20 PM
$ANIP (+6.2% pre) ANI: Q1 Earnings Snapshot https://ooc.bz/l/64143
0 · Reply
mikesterz7
mikesterz7 May. 9 at 11:37 AM
$ANIP 🚨 ANI Pharma reported Q1 EPS of $1.70, $0.36 better than the analyst estimate of $1.34. Revenue for the quarter came in at $197.1 million versus the consensus estimate of $179.21 million. GUIDANCE: ANI Pharma sees FY2025 EPS of $6.27-$6.62, versus the consensus of $6.34. ANI Pharma sees FY2025 revenue of $768-793 million, versus the consensus of $769.6 million.
0 · Reply
DonCorleone77
DonCorleone77 May. 9 at 11:01 AM
$ANIP ANI Pharmaceuticals raises FY25 adj. EPS view to $6.27-$6.62 from $6.12-$6.49 Raises FY25 revenue view to $768M-$793M from $756M-$776M, consensus $769.64M. Sees FY25 adjusted EBITDA $195M-$205M. @Doozio
0 · Reply
DonCorleone77
DonCorleone77 May. 9 at 11:01 AM
$ANIP ANI Pharmaceuticals reports Q1 adjusted EPS $1.70 vs. $1.21 last year Reports Q1 revenue $197.1M vs. $137.43M last year. "We are pleased to report another strong quarter, with record revenue, adjusted EBITDA and adjusted EPS driven by continued strong demand for Cortrophin Gel, exceptional performance for our Generics business, and increased demand for our Brands portfolio," said Nikhil Lalwani, President and CEO of ANI. "Our lead Rare Disease product Cortrophin Gel continued to perform well delivering a record number of prescriptions and new patient starts in the first quarter." Lalwani continued, "While our core franchises outperformed, demand for our retina assets ILUVIEN and YUTIQ was impacted by Medicare-related market access challenges, turnover in our ophthalmology sales team, and seasonality. We remain focused on growing our retina franchise and are pleased to report that demand has accelerated in the second quarter. Based on our first quarter performance and favorable demand trends for Cortrophin Gel and our Generics and Brands portfolio, we are raising our 2025 guidance for total revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP EPS. While we await more visibility on potential pharmaceutical industry-specific tariffs, we believe we are well positioned based on our strong U.S. footprint with over 90% of our revenues coming from finished goods manufactured in the U.S. and less than 5% of our revenues with direct reliance on China." cc: @Doozio
0 · Reply